Genmab A/S (GMAB)
$37.07+2.83%Close
BUYBULL · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $22.8B
- Beta
- 0.70
- P/E (TTM)
- 29.18
- Short % float
- 1.00%
- Days to cover
- 2.1
- SI change
- +23.2%
- 1W
- +6.68%
- 1M
- +15.02%
- vs SPY 1W
- +5.52%
- vs SPY 1M
- +12.02%
Industry peers
FMP comparable companies · ranked by market cap
- BNTXSELLBioNTech SE$23.1BRECOVERYQ 35$92.06+5.32%
- INCYSELLIncyte Corporation$22.9BBEARQ 13$112.75+0.04%
- EXELBUYExelixis, Inc.$14.8BBULLQ 10$59.02+1.42%
- IOVABUYIovance Biotherapeutics, Inc.$5.9BRECOVERYQ 9$13.31+9.84%
- LEGNSELLLegend Biotech Corporation$3.5BRECOVERYQ 2$18.71-0.48%
- RCUSSELLArcus Biosciences, Inc.$3.0BRECOVERYQ 17$23.83+2.43%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on GMAB?
- LOPJLB’s latest quantitative signal on Genmab A/S (GMAB) is BUY in a BULL regime. Signals are updated daily.
- What market regime is GMAB in?
- Genmab A/S (GMAB) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Genmab A/S (GMAB) do?
- Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-M…